ClinicalTrials.gg
CompletedNCT03182140KYSSUpdated Mar 29, 2021

KYleena Satisfaction Study / Observational Study on User Satisfaction With the Levonorgestrel Intrauterine Delivery System Kyleena (LNG-IUS 12) in New Contraceptive Users and After Switching From Another Contraceptive Method

An observational study in Contraception, sponsored by Bayer. Completed at 19 sites in 8 countries. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-29.

Sponsored by Bayer · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,134
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 91 studies in Personal Satisfaction with a site in United States — 6 open to participants now, 8 under way, none of them phase 3. Personal Satisfaction · United States.

Enrollment
2nd of 11
1,134 · median 83
Started
2017
with 6 others
Observational
11 of 91
2 open now
Registered
41st of 91
by date

Among the 91 studies in Personal Satisfaction with a site in United States, this one is the 2nd largest by enrollment of the 11 observational ones that give a count, is one of 7 that started in 2017, is one of 11 observational ones, and was the 41st registered.

Personal Satisfaction

543 studies on the registry are indexed under Personal Satisfaction; 91 are open to participants now.

Browse Personal Satisfaction studies →

Open to participants now

6 of the 91 studies in Personal Satisfaction with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Personal Satisfaction studies recruiting now, 18 (47%) set no upper age limit and 15 (39%) stop at 75 or younger; 8 take children under 18; 20 take healthy volunteers.

This study: female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Personal Satisfaction with a site in United States, or all of them as a file.
02

Study summary

The main goal of this non-interventional study (NIS) is to evaluate user satisfaction with Kyleena in a real-life setting and to identify factors which influence user satisfaction, taking into account previously used contraceptive methods and reasons for use of Kyleena.

03

Conditions studied

  • Contraception

Keywords

  • long-acting contraception,
  • unintended pregnancy
  • satisfaction
  • bleeding profile
  • amenorrhea
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Women in the respective participating country requesting contraception with Kyleena will be eligible to be enrolled.

Women can be screened for the study only after an informed decision for Kyleena has been made by the woman and the treating health care professional such as her physician/gynecologist or midwife. Indication and contraindications according to the local market authorization/ summary of product characteristics (SmPC) should be carefully considered.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women requesting with Kyleena. The woman's informed decision for contraception with Kyleena was made before and independently from the study as per investigator's routine practice
  • Written .

Exclusion criteria

Exclusion Criteria:

  • for Kyleena according to the local market authorization/SmPC
  • Mental incapacity to consent and provide data during the observational study
  • Women participating in an program with interventions outside of routine clinical practice.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,134 participants (actual)
Patient registry
No

Groups and cohorts

  • Kyleena

    Non-interventional, observational, uncontrolled study in women that have chosen Kyleena as their contraceptive method before entering the study

    Drug: Kyleena

Interventions

  • DrugKyleena

    Kyleena - intrauterine delivery system containing 19.5 mg LNG

06

What researchers measure

Primary outcomes

  1. Overall satisfaction with Kyleena assessed by questionnaire

    The rating is based on the 5-item Likert scale (very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied, very dissatisfied).

    Time frame: approximately at 12 months after insertion or at premature discontinuation

Secondary outcomes

  1. Overall satisfaction with Kyleena assessed by questionnaire

    The rating is based on the 5-item Likert scale (very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied, very dissatisfied).

    Time frame: approximately 4-12 weeks after insertion

  2. Ease of insertion assessed by investigator

    The rating is based on the categories easy, slightly difficult, very difficult.

    Time frame: Day 1

  3. Pain at insertion assessed by participant

    The rating is based on the categories none, mild, moderate, or severe

    Time frame: Day 1

  4. Satisfaction with the menstrual bleeding profile with Kyleena assessed by questionnaire

    Satisfaction with the menstrual bleeding profile with Kyleena assessed by women who did and did not experience menstrual bleeding during the last three months when answering the question "How satisfied were you with your menstrual bleeding pattern?" respectively. The rating is based on the 5-item Likert scale (very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied, very dissatisfied).

    Time frame: after approximately 12 months or at premature discontinuation and approximately 4-12 weeks after insertion

07

Study locations

19 sites
  • Jennifer Grube, MD, FACOG
    Lakewood, Colorado 80228, United States
  • Physician Care Clinical Research LLC
    Sarasota, Florida 34239, United States
  • Visions Clinical Research
    Wellington, Florida 33414, United States
  • New England Center for Clinical Research Primacare Research, LLC
    Fall River, Massachusetts 02721, United States
  • Saginaw Valley Medical Research Group, LLC
    Saginaw, Michigan 48604, United States
  • Lawrence OB/GYN Clinical Research, LLC
    Lawrenceville, New Jersey 08648, United States
  • ProHEALTH Care Associates
    Port Jefferson, New York 11777, United States
  • Eastern Carolina Women's Center
    New Bern, North Carolina 28562, United States
  • Radiant Research
    Akron, Ohio 44311, United States
  • TMC Life Research
    Houston, Texas 77054, United States
  • Physician's Research
    Draper, Utah 84020, United States
  • Physician's Research Options LLC - Revere Women's Health OB/GYN Clinic
    Pleasant Grove, Utah 84062, United States
  • Many locations
    Multiple Locations, Belgium
  • Many locations
    Multiple Locations, Canada
  • Many locations
    Multiple Locations, Germany
  • Many locations
    Multiple Locations, Mexico
  • Many locations
    Multiple Locations, Norway
  • Many locations
    Multiple Locations, Spain
  • Many locations
    Multiple Locations, Sweden
08

References and documents

Publications

  • Stovall DW, Aqua K, Romer T, Donders G, Sordal T, Hauck B, Llata ES, Kallner HK, Salomon J, Zvolanek M, Frenz AK, Bohnke T, Bauerfeind A. Satisfaction and continuation with LNG-IUS 12: findings from the real-world kyleena(R) satisfaction study. Eur J Contracept Reprod Health Care. 2021 Dec;26(6):462-472. doi: 10.1080/13625187.2021.1975268. Epub 2021 Sep 16. PubMed 34528857 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Dec 2019, 29 months.

Of 44 observational studies under Personal Satisfaction, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 29. This study's 29 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2017
First posted
Jun 9, 2017
StartActual
Jul 6, 2017
Primary completionActual
Dec 19, 2019
CompletionActual
Mar 31, 2020
Last update
Mar 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03182140
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jun 9, 2017
Start date
Jul 6, 2017
Primary completion
Dec 19, 2019
Completion
Mar 31, 2020
Last update
Mar 29, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion